reports
Liquidia to Present Clinical Data Across Its Portfolio at the Pulmonar...
Liquidia to Present Clinical Data Across Its Portfolio at the Pulmonary Vascular Research Institute 2026 Annual Congress MORRISVILLE, N.C., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today the company will present three posters at the Pulmonary Vascular Research Institute (PVRI) 2026 Annual Congress to be held January 28 through February 1, 2026, in Dublin, Ireland. The presentations highlight clinical data in pulmonary arterial hypertensi...
BlackRock® Canada Announces Final January Cash Distributions for the i...
BlackRock® Canada Announces Final January Cash Distributions for the iShares® Premium Money Market ETF TORONTO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- BlackRock Asset Management Canada Limited (“BlackRock Canada”), an indirect, wholly-owned subsidiary of BlackRock, Inc. (NYSE: BLK), today announced the final January 2026 cash distributions for the iShares Premium Money Market ETF. Unitholders of record on January 27, 2026 will receive cash distributions payable on January 30, 2026. Details regarding the final “per unit” distribution amounts are as follows: Fund NameFund TickerCash Distributio...
BlackRock® Canada Announces January Cash Distributions for the iShares...
BlackRock® Canada Announces January Cash Distributions for the iShares® ETFs TORONTO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- BlackRock Asset Management Canada Limited (“BlackRock Canada”), an indirect, wholly-owned subsidiary of BlackRock, Inc. (NYSE: BLK), today announced the January 2026 cash distributions for the iShares ETFs listed on the TSX or Cboe Canada which pay on a monthly basis. Unitholders of record of the applicable iShares ETF on January 27, 2026 will receive cash distributions payable in respect of that iShares ETF on January 30, 2026. Details regarding the “per unit” distribu...
AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scie...
AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced its participation in the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), which took place on January 12 - 15, 2026 in Nassau, The Bahamas. The Company present...
IMDX Supports AST and ASHI STAR Working Group’s Call for Decentralized...
IMDX Supports AST and ASHI STAR Working Group’s Call for Decentralized Transplant Monitoring American Journal of Transplantation position paper also highlights value of absolute quantification of dd-cfDNA as a diagnostic marker, a key feature of iMDx’s flagship GraftAssureTM family of assays NASHVILLE, Tenn., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today congratulated the STAR working group on its position paper in the American Journal of Transplantation in recognizing the need for decentralized organ health testing in the global tran...
Liquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net...
Liquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net Sales and Corporate Update Estimated YUTREPIA™ net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year 2025Received more than 2,800 unique patient prescriptions since launch in June 2025Generated more than $30 million of positive cash flow during the fourth quarter 2025 MORRISVILLE, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging ...
AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan ...
AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today provided its outlook for 2026 ahead of attendance at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco, California, on January 12 – 15, 2026. Dr Srinivas Rao, Co-Founder and Chief Executive Officer of AtaiBe...
iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation
iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation NASHVILLE, Tenn., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., or iMDx, (Nasdaq: IMDX), today announced members of its management team will participate in the following investor conferences this winter, which will include hosting meetings around the annual J.P. Morgan Healthcare Conference. LifeSci Advisors 15th Annual Corporate Access Event Date: Monday, January 12thLocation: The Beacon Grand, San Francisco, Calif.Format: One-on-one meetings with management Additional “JPM Week” Investor Mee...
Liquidia Corporation to Present at 44th Annual J.P. Morgan Healthcare ...
Liquidia Corporation to Present at 44th Annual J.P. Morgan Healthcare Conference MORRISVILLE, N.C., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Dr. Roger Jeffs, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 beginning at approximately 5:15 p.m. Pacific Time (8:15 p.m. Eastern Time) at the Westin St. Francis in San Francisco, California. Access to a live, audio-only webcast will be available on the “Investors” page of Liquidia’s website at . The webcast will be archive...
iMDx to Welcome Industry Veteran as Vice President of Medical Affairs ...
iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch Dr. Nick Ioannou brings decades of academia, industry, and clinical experience in organ transplant, nephrology, cardiology, genetics, and oncology NASHVILLE, Tenn., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), or iMDx, today announced that it has appointed Dr. Nick Ioannou, M.D., MHA, to the position of Vice President, Medical Affairs. Dr. Ioannou is a physician-scientist with more than three decades of highly relevant experienc...
iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical ...
iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion GraftAssure™ technology adoption further broadens with 20 global transplant centers engaged by year-end 2025, including first Canadian siteGraftAssureDx™ FDA IVD approval application 95% complete at year-end; expect full submission in coming weeksAccelerating planned UK CE mark and EU IVDR submission to first half 2026, following successful TÜV SÜD ISO 13485 stage 1 & 2 audit completions in Q4 2025Strong engagement from clinical community on GraftAssureCore™ kidney registry with 17 U.S. transplant c...
AtaiBeckley Completes Redomiciliation to the United States
AtaiBeckley Completes Redomiciliation to the United States NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced the completion of the redomiciliation of the parent company of the AtaiBeckley group from a Netherlands company to a U.S. entity incorporated in Delaware. The redomiciliation was approved by approximately 99% of the votes cast at the Company’s extra...
BlackRock® Canada Announces Final Annual Reinvested Capital Gains Dist...
BlackRock® Canada Announces Final Annual Reinvested Capital Gains Distributions for the iShares® ETFs TORONTO, Dec. 30, 2025 (GLOBE NEWSWIRE) -- BlackRock Asset Management Canada Limited (“BlackRock Canada”), an indirect, wholly-owned subsidiary of BlackRock, Inc. (NYSE: BLK), today announced the final annual reinvested capital gains distributions for the iShares ETFs listed on the TSX or Cboe Canada for the 2025 tax year. The distributions are for the annual non-cash capital gains distributions, which are typically reinvested in additional units of the respective funds at the year-end, ...
BlackRock® Canada Announces Final December Cash Distributions for the ...
BlackRock® Canada Announces Final December Cash Distributions for the iShares® ETFs TORONTO, Dec. 29, 2025 (GLOBE NEWSWIRE) -- BlackRock Asset Management Canada Limited (“BlackRock Canada”), an indirect, wholly-owned subsidiary of BlackRock, Inc. (NYSE: BLK), today announced the final December cash distributions for the iShares ETFs listed on the TSX or Cboe Canada. Unitholders of record of a fund on December 30, 2025 will receive cash distributions payable in respect of that fund on January 5, 2026. Details regarding the “per unit” distribution amounts are as follows: Fund NameFund Tick...
AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)
AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI) NEW YORK and AMSTERDAM, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced its common stock has been added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 22, 2025. “2025 has been a defining year for AtaiBeckley, marked by meaningful progress across our pip...
BlackRock® Canada Announces Estimated December Cash Distributions for ...
BlackRock® Canada Announces Estimated December Cash Distributions for the iShares® ETFs TORONTO, Dec. 22, 2025 (GLOBE NEWSWIRE) -- BlackRock Asset Management Canada Limited (“BlackRock Canada”), an indirect, wholly-owned subsidiary of BlackRock, Inc. (NYSE: BLK), today announced the estimated December cash distributions for the iShares ETFs listed on the TSX or Cboe Canada. Unitholders of record of a fund on December 30, 2025 will receive cash distributions payable in respect of that fund on January 5, 2026. BlackRock Canada expects to issue a press release on or about December 29, 2025,...
BlackRock® Canada Announces Estimated Annual Reinvested Capital Gains ...
BlackRock® Canada Announces Estimated Annual Reinvested Capital Gains Distributions for the iShares® ETFs TORONTO, Dec. 22, 2025 (GLOBE NEWSWIRE) -- BlackRock Asset Management Canada Limited (“BlackRock Canada”), an indirect, wholly-owned subsidiary of BlackRock, Inc. (NYSE: BLK), today announced the estimated annual reinvested capital gains distributions for the iShares ETFs listed on the TSX or Cboe Canada for the 2025 tax year. Please note that these are estimated amounts only as of December 15, 2025 and could change if the iShares Funds experience subscriptions or redemptions prior to...
AtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthenin...
AtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthening Intellectual Property Portfolio NEW YORK and AMSTERDAM, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced that the United States Patent and Trademark Office has granted a new patent covering EMP-01 (oral R-MDMA), further strengthening the company’s intellectual property estate and long-term...
Sensient Technologies Corp: 1 director
A director at Sensient Technologies Corp sold 4,518 shares at 94.809USD and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
Blackrock Inc: 1 director
A director at Blackrock Inc sold 1,258 shares at 1,043.380USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.